Advertisement


Yousuf Zafar, MD, on the Financial Burden of Cancer Care

2016 ASCO Annual Meeting

Advertisement

Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.



Related Videos

Gynecologic Cancers

Eric Roeland, MD, and Linda Van Le, MD, on Gynecologic Cancers: Managing Menopausal Symptoms in Survivors

Eric Roeland, MD, of the University of California, San Diego, and Linda Van Le, MD, of the University of North Carolina discuss ways to manage symptoms that affect up to 80% of postmenopausal women, diminishing their quality of life.

Gynecologic Cancers

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).

Global Cancer Care

Nagi S. El-Saghir, MD, PhD, and Mary Gospodarowicz, MD, on The Middle Eastern Perspective of Cancer Research

Nagi S. El-Saghir, MD, of the American University of Beirut, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

Daniel F. Hayes, MD, ASCO President 2016–2017, on His Goals for the Coming Year

Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.

Gynecologic Cancers

Helen MacKay, MD, and Ursula A. Matulonis, MD, on Epithelial Ovarian Cancer: Results From the OV21-PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, and Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discuss findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).

Advertisement

Advertisement




Advertisement